0000000000713167
AUTHOR
Tim Liedl
showing 2 related works from this author
Unraveling the interaction between doxorubicin and DNA origami nanostructures for customizable chemotherapeutic drug release
2021
We thank Dr H. Häkkänen for technical assistance and S. Julin for the 24HB DNA origami design. We acknowledge the provision of facilities and technical support by Aalto University Bioeconomy Facilities and OtaNano – Nanomicroscopy Center (Aalto-NMC). The research was carried out under the Academy of Finland Centres of Excellence Programme (2014–2019). Academy of Finland [308578 to M.A.K.]; Deutsche Forschungsgemeinschaft [Emmy Noether Programme to A.H.-J., SFB1032 (Project A06) to T.L.]; Emil Aaltonen Foundation [to H.I. and V.L.]; Jane and Aatos Erkko Foundation [to J.A.I. and V.L.]; Sigrid Jusélius Foundation [to V.L.]; Vilho, Yrjö and Kalle Väisälä Foundation of the Finnish Academy of Sc…
Unraveling the interaction between doxorubicin and DNA origami nanostructures for customizable chemotherapeutic drug release
2020
Doxorubicin (DOX) is a commonly employed drug in cancer chemotherapy, and its high DNA-binding affinity can be harnessed in preparing programmable DOX-loaded DNA nanostructures that can be further tailored for targeted delivery and therapeutics. Although DOX has been widely studied, the existing literature of promising DOX-loaded DNA nanocarriers remains limited and incoherent. A number of reports have over-looked the fundamentals of the DOX-DNA interaction, let alone the peculiarities arising from the complexity of the system as a whole. Here, based on an in-depth spectroscopic analysis, we characterize and optimize the DOX loading into different 2D and 3D scaffolded DNA origami nanostruct…